Adaptive Clinical Trials as Topic
"Adaptive Clinical Trials as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Works about clinical studies in which a prospectively planned opportunity is included to modify trial designs and hypotheses based on analysis of data from subjects in the study .
| Descriptor ID |
D000075522
|
| MeSH Number(s) |
E05.318.760.250.500.100 N05.715.360.775.088.500.100 N06.850.520.450.250.250.100
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Adaptive Clinical Trials as Topic".
Below are MeSH descriptors whose meaning is more specific than "Adaptive Clinical Trials as Topic".
This graph shows the total number of publications written about "Adaptive Clinical Trials as Topic" by people in this website by year, and whether "Adaptive Clinical Trials as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 3 | 3 |
| 2024 | 0 | 1 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adaptive Clinical Trials as Topic" by people in Profiles.
-
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial. Ann Surg Oncol. 2025 Oct; 32(11):8113-8126.
-
Shock prediction with dipeptidyl peptidase-3 and renin (SPiDeR) in hypoxemic patients with COVID-19. J Crit Care. 2025 Feb; 85:154950.
-
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial. JAMA Surg. 2022 11 01; 157(11):1034-1041.
-
Optimizing the Design and Analysis of Future AKI Trials. J Am Soc Nephrol. 2022 08; 33(8):1459-1470.
-
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022 06 13; 40(6):609-623.e6.
-
The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions. J Allergy Clin Immunol. 2022 02; 149(2):488-516.e9.
-
PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment. J Allergy Clin Immunol. 2021 05; 147(5):1594-1601.
-
The precision interventions for severe and/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations. J Biopharm Stat. 2020 11 01; 30(6):1026-1037.